Brief: Coya Therapeutics To Present Biomarker And Preliminary Efficacy Clinical Data For Coya 301 For The Treatment Of Patients With Alzheimer’S Disease (Ad) At The 2023 Keystone Symposia Meeting For Neurodegeneration Held On May 15-19Th, 2023
31/03/2023 12:09
March 31 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS TO PRESENT BIOMARKER AND PRELIMINARY
EFFICACY
CLINICAL DATA FOR COYA 301 FOR THE TREATMENT OF PATIENTS WITH
ALZHEIMER’S DISEASE (AD) AT THE 2023 KEYSTONE SYMPOSIA MEETING
FOR NEURODEGENERATION HELD ON MAY 15-19TH, 2023
Source text for Eikon: ID:nBwbLKFv7a
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)